Welcome to LookChem.com Sign In|Join Free
  • or

856867-55-5

Post Buying Request

856867-55-5 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Tedizolid Phosphate
Cas No: 856867-55-5
USD $ 999.0-999.0 / Gram 1 Gram 1 Metric Ton/Month Shanghai Run-Biotech Co., Ltd. Contact Supplier
tedizolide Phophate
Cas No: 856867-55-5
No Data 1 Gram 5 Metric Ton/Month Shanghai SE Pharm Co., Ltd Contact Supplier
Factory Supply Good Price Quality, Tedizolid phosphate
Cas No: 856867-55-5
USD $ 200.0-300.0 / Gram 1 Gram 50 Kilogram/Month Beijing Yibai Biotechnology Co., Ltd Contact Supplier
Tedizolid Phosphate
Cas No: 856867-55-5
No Data 1 Gram Metric Ton/Day Koning Pharmchem Co., Ltd. Contact Supplier
Tedizolid phosphate
Cas No: 856867-55-5
No Data No Data No Data Chemwill Asia Co., Ltd. Contact Supplier
Tedizolid
Cas No: 856867-55-5
USD $ 1.0-2.0 / Gram 10 Gram 100 Kilogram/Day Hangzhou Dayangchem Co., Ltd. Contact Supplier
Factory supply Tedizolid Phosphate cas 856867-55-5 with best price
Cas No: 856867-55-5
No Data No Data 1000 Metric Ton/Month Crovell Biotech (Hebei) Co., Ltd. Contact Supplier
856867-55-5 C17H18FN6O7P TR-701 FA
Cas No: 856867-55-5
No Data 1 Kilogram 100-200 Kilogram/Month HENAN SUNLAKE ENTERPRISE CORPORATION Contact Supplier
high quality 856867-55-5 Tedizolid Phosphate with best price
Cas No: 856867-55-5
No Data 10 Gram 1000 Metric Ton/Month Hubei XinRunde Chemical Co., Ltd Contact Supplier
high quality 99%Tedizolid phosphate CasNo856867-55-5
Cas No: 856867-55-5
No Data 10 Gram 1000 Metric Ton/Month HUBEI AOKS BIO-TECH CO.,LTD Contact Supplier

856867-55-5 Usage

A new antibacterial drug

Tedizolid phosphate is a new anti-bacterial drug developed by CUBIST PHARMS company. Tedizolid phosphate is a prodrug of Tedizolid. After oral or intravenous administration, Tedizolid phosphate is converted to Tedizolid by phosphatase. Tedizolid is the second generation of oxazolidinone antibiotics, a protein synthesis inhibitors. binding the 50S subunit of bacterial ribosomes, it can inhibit protein synthesis and play a role of antibacterial. It  is not easy to have  cross-resistance with other types of antibiotics, and has a longer half-life compared to linezolid.
On June 20, 2014, the US Food and Drug Administration (FDA) approved Tedizolid phosphate for use in certain sensitive bacterial-induced adult acute bacterial skin and skin structure infections (ABSSSI), with trade name SIVEXTRO, specification 200 mg. Tedizolid phosphate has been submitted a listing application in Europe and Canada currently, while the drug has not yet listed in China. Tedizolid's listing application is based on clinical trials ESTABLISH 1 and ESTABLISH 2. The results showed that Tedizolid achieved its primary endpoint and secondary endpoint in clinical trials of ABSSSI (defined by the FDA and the European Medicines Agency).
Clinical studies have shown that Tedizolid not only has a better clinical efficacy, and but shortened the treatment cycle by 40% compared with linezolid.
In addition, the study of Tedizolid for hospital acquired/ventilator-associated bacterial pneumonia (HABP/VABP) has entered the clinical phase II.
Analyst Larry Smith predicts the drug will sell more than $ 1 billion by 2020.
This information was edited by Xiao Nan from Chemicalbook (2015-08-14).

Indications

Tedizolid (Tedizolid Phosphate, Tidizolamide) is oxazolidinone compounds for serious Gram-positive bacterial infection treatment:
Acute bacterial skin and skin structure infections and complex skin and soft tissue infections (absssi/cSSTI, IV/oral) (to be approved).
Hospital Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP) (Clinical Phase II).
SIVEXTRO is a class of oxazolidinone-based antimicrobials designed for Acute bacterial skin and skin structure infections (ABSSSI). In order to reduce the development of resistant bacteria and to maintain the effectiveness of SIVEXTRO and other antimicrobial agents, SIVEXTRO should only be used to treat or prevent infections that have been proven or strongly suspected to be bacterial-induced.

Definition

ChEBI: A phosphate monoester resulting from the formal condensation of equimolar amounts of phosphoric acid with the hydroxy group of tedizolid . It is a prodrug of tedizolid, used for the treatment of acute bacterial skin infections caused by certain susceptibl bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.

856867-55-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name tedizolid phosphate

1.2 Other means of identification

Product number -
Other names Tedizolid phosphate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:856867-55-5 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields